Annual Financial Results as of December 31, 2017
30/04/2018 – AB Science reports on its annual financials as of 31 December 2017 and provides an update on its activities.
30/04/2018 – AB Science reports on its annual financials as of 31 December 2017 and provides an update on its activities.
19/04/2018 – AB Science will provide additional data through a reexamination procedure
Praesent nec lectus eu neque fringilla volutpat. Nulla tristique ullamcorper quam, ut dapibus massa hendrerit ac. Etiam a tempus lectus. Proin nibh nisi, vehicula non enim sed, venenatis faucibus orci. Fusce ut elementum nunc, vel eleifend sem.
Suspendisse ex justo, lacinia nec iverra bel, lacinia id lorem. Sed turpis eget sem accumsan viverra
Nulla dui fusce feugiat malesuada odiorbi nunc odio gravida at cursus nec luctus a lorem aecenas tristique orci acsemuis ultricies pharetra magna.
04/01/2018 – Additionally, the IDMC did not report any safety concern with masitinib in the study population.
European Hematology Association June 2017 22/06/2017 – MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBOCONTROLLED, PHASE 3 STUDY
Abstract O. Hermine Industry’s Perspective 2016 01/07/2016 – Development of masitinib, a novel tyrosine kinase inhibitor and immunotherapeutic, for the treatment of peripheral T-cell lymphoma
Montagne-Neuron-2015 21/01/2015 – Blood-Brain Barrier Breakdown in the Aging Human Hippocampus Volonte CNSND-DT Author corrected PROOFS 15/12/2014 – New Kid on the Block: Dœs Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis? PlosOne – Mast Cells in Gastric Cancer 08/09/2014 – Intratumor IL-17-Positive Mast Cells are the major source of the IL-17 that is…